Literature DB >> 28943232

Daily Opioid Use Fluctuates as a Function of Pain, Catastrophizing, and Affect in Patients With Sickle Cell Disease: An Electronic Daily Diary Analysis.

Patrick H Finan1, C Patrick Carroll2, Gyasi Moscou-Jackson2, Marc O Martel3, Claudia M Campbell2, Alex Pressman2, Joshua M Smyth4, Jean-Michel Tremblay2, Sophie M Lanzkron5, Jennifer A Haythornthwaite2.   

Abstract

Chronic opioid therapy is a common treatment regimen for patients with sickle cell disease (SCD), a chronically painful recessive hemoglobinopathy. The collective risk profile of chronic opioid therapy necessitates an understanding of which pain-related factors, such as affect and pain catastrophizing, are associated with the ebbs and flows of opioid use in daily life, a topic that has received very little attention among patients with any type of chronically painful condition, including SCD. We therefore investigated the variability of day-to-day patterns of short- and long-acting opioid use and their associations with pain and pain-related cognitive and affective processes in daily life among patients with SCD using a nightly electronic diary (N = 45). Opioid use was self-reported and converted into oral morphine equivalents for analysis, which was conducted with mixed effects modeling. Results indicated that greater pain and pain catastrophizing were associated with greater use of short-acting opioids, and negative affect was associated with greater use of long-acting opioids. Additionally, the association of pain and short-acting opioid use was moderated by pain catastrophizing, showing that opioid use was elevated when patients catastrophized about their pain, even if they reported low levels of pain. These findings suggest that monitoring pain-related cognitive and affective variables may be a useful approach to understanding risk for problematic opioid use in patients with daily pain. PERSPECTIVE: The present study shows that pain and pain-related cognitive and affective variables are associated with daily variation in prescription opioid use in SCD. The findings may have broad implications for tracking and defining risk for prescription opioid misuse in patients with daily pain.
Copyright © 2017 The American Pain Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Opioid use; affect; catastrophizing; pain; sickle cell disease

Mesh:

Year:  2017        PMID: 28943232      PMCID: PMC5820769          DOI: 10.1016/j.jpain.2017.08.010

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  44 in total

Review 1.  Theoretical perspectives on the relation between catastrophizing and pain.

Authors:  M J Sullivan; B Thorn; J A Haythornthwaite; F Keefe; M Martin; L A Bradley; J C Lefebvre
Journal:  Clin J Pain       Date:  2001-03       Impact factor: 3.442

2.  Opioids and methadone equivalents for clinicians.

Authors:  W Victor R Vieweg; William F Carlyle Lipps; Antony Fernandez
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 3.  Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction.

Authors:  Bridget A Martell; Patrick G O'Connor; Robert D Kerns; William C Becker; Knashawn H Morales; Thomas R Kosten; David A Fiellin
Journal:  Ann Intern Med       Date:  2007-01-16       Impact factor: 25.391

4.  Chronic Opioid Therapy and Central Sensitization in Sickle Cell Disease.

Authors:  C Patrick Carroll; Sophie Lanzkron; Carlton Haywood; Kasey Kiley; Megan Pejsa; Gyasi Moscou-Jackson; Jennifer A Haythornthwaite; Claudia M Campbell
Journal:  Am J Prev Med       Date:  2016-07       Impact factor: 5.043

5.  Psychosocial effects of sickle cell disease.

Authors:  C F Whitten; J Fischhoff
Journal:  Arch Intern Med       Date:  1974-04

Review 6.  Methadone--metabolism, pharmacokinetics and interactions.

Authors:  Anna Ferrari; Ciro Pio Rosario Coccia; Alfio Bertolini; Emilio Sternieri
Journal:  Pharmacol Res       Date:  2004-12       Impact factor: 7.658

7.  The relationship of gender to pain, pain behavior, and disability in osteoarthritis patients: the role of catastrophizing.

Authors:  Francis J Keefe; John C Lefebvre; Jennifer R Egert; Glenn Affleck; Michael J Sullivan; David S Caldwell
Journal:  Pain       Date:  2000-09       Impact factor: 6.961

Review 8.  Pain catastrophizing: a critical review.

Authors:  Phillip J Quartana; Claudia M Campbell; Robert R Edwards
Journal:  Expert Rev Neurother       Date:  2009-05       Impact factor: 4.618

9.  De facto long-term opioid therapy for noncancer pain.

Authors:  Michael Von Korff; Michael Von Korff; Kathleen Saunders; Gary Thomas Ray; Denise Boudreau; Cynthia Campbell; Joseph Merrill; Mark D Sullivan; Carolyn M Rutter; Michael J Silverberg; Caleb Banta-Green; Constance Weisner
Journal:  Clin J Pain       Date:  2008 Jul-Aug       Impact factor: 3.442

10.  Do pain patients at high risk for substance misuse experience more pain? A longitudinal outcomes study.

Authors:  Robert N Jamison; Carol L Link; Lisa D Marceau
Journal:  Pain Med       Date:  2009-08-07       Impact factor: 3.750

View more
  19 in total

1.  Effect of chronic opioid therapy on pain and survival in a humanized mouse model of sickle cell disease.

Authors:  Huy Tran; Varun Sagi; Waogwende Leonce Song-Naba; Ying Wang; Aditya Mittal; Yann Lamarre; Lei Zhang; Kalpna Gupta
Journal:  Blood Adv       Date:  2019-03-26

Review 2.  Targeting pain at its source in sickle cell disease.

Authors:  Kanika Gupta; Om Jahagirdar; Kalpna Gupta
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-03-28       Impact factor: 3.619

3.  Red blood cell transfusion therapy for sickle cell patients with frequent painful events.

Authors:  Lee M Hilliard; Varsha Kulkarni; Bisakha Sen; Cathy Caldwell; Christina Bemrich-Stolz; Thomas H Howard; Amanda Brandow; Emily Waite; Jeffrey D Lebensburger
Journal:  Pediatr Blood Cancer       Date:  2018-08-27       Impact factor: 3.167

4.  Daily Associations between Child and Parent Psychological Factors and Home Opioid Use in Youth with Sickle Cell Disease.

Authors:  Amanda L Stone; Zaria Williams; Melissa McNaull; Anna C Wilson; Cynthia W Karlson
Journal:  Ann Behav Med       Date:  2020-01-01

Review 5.  Optimizing the management of chronic pain in sickle cell disease.

Authors:  Ifeyinwa Osunkwo; Hazel F O'Connor; Elna Saah
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

6.  A Preliminary Investigation of the Underlying Mechanism Associating Daily Sleep Continuity Disturbance and Prescription Opioid Use Among Individuals With Sickle Cell Disease.

Authors:  Chung Jung Mun; Patrick H Finan; Michael T Smith; C Patrick Carroll; Joshua M Smyth; Sophie M Lanzkron; Jennifer A Haythornthwaite; Claudia M Campbell
Journal:  Ann Behav Med       Date:  2021-06-02

Review 7.  Emotion regulation as a transdiagnostic factor underlying co-occurring chronic pain and problematic opioid use.

Authors:  Rachel V Aaron; Patrick H Finan; Stephen T Wegener; Francis J Keefe; Mark A Lumley
Journal:  Am Psychol       Date:  2020-09

8.  Patterns of opioid use in adolescents receiving prescriptions: The role of psychological and pain factors.

Authors:  Anna C Wilson; Benjamin J Morasco; Amy L Holley; Sarah W Feldstein Ewing
Journal:  Am Psychol       Date:  2020-09

9.  Psychosocial and Clinical Risk Factors Associated with Substance Use in Observational Cohort of Patients with Sickle Cell Disease.

Authors:  J Deanna Wilson; Sophie Lanzkron; Lydia H Pecker; Shawn M Bediako; Dingfen Han; Mary Catherine Beach
Journal:  Subst Use Misuse       Date:  2020-08-07       Impact factor: 2.164

Review 10.  Cognitive-Affective Transdiagnostic Factors Associated With Vulnerability to Alcohol and Prescription Opioid Use in the Context of Pain.

Authors:  Emily L Zale; Jessica M Powers; Joseph W Ditre
Journal:  Alcohol Res       Date:  2021-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.